Results 201 to 210 of about 154,739 (326)

Leveraging transcriptomic, DNA methylation, and molecular alteration data to optimize the classification of IDH-mutant gliomas for therapy selection. [PDF]

Front Oncol
Gonzalez Castro LN.
europepmc   +1 more source

Multi-center real-world data-driven web calculator for predicting outcomes in IDH-mutant gliomas: Integrating molecular subtypes and treatment modalities [PDF]

Houshi Xu, Bin Liu, Yue Wang, Ruize Zhu, Shan Jiang, Lina Akmal Fouad Abdelhamid Soliman, Huihui Chai, Maoyuan Sun, Jiawen Chen, Kay Ka-Wai Li, Ho‐Keung Ng, Zhenyu Zhang, Junji Wei, Zhifeng Shi, Ying Mao   +14 more
openalex   +1 more source

Radiogenomics: Current Understandings and Future Perspectives

MedComm, Volume 7, Issue 2, February 2026.
Radiogenomics links imaging phenotypes with genetic variations, offering potential for comprehensive understanding, cost‐effective diagnosis, and prognosis prediction to advance personalized medicine. However, its clinical application remains limited by several challenges.
Xinyu Zhang, Qingpei Lai, Jin Cao, Jerry Chi Fung Ching, Xinzhi Teng, Jiang Zhang, Shara Wee Yee Lee, Ge Ren, Jing Cai   +8 more
wiley   +1 more source

Unilateral biportal endoscopic surgery for intradural lumbar disc herniation: illustrative case. [PDF]

J Neurosurg Case Lessons
Xu X, Jamal AH, Wang Z, Chen J, Chang X, Yang J, Zhang Z.   +6 more
europepmc   +1 more source

P01.075 Understanding cognitive functioning in diffuse glioma patients: the relevance of IDH mutation status and functional connectivity [PDF]

, 2018
Jolanda Derks, Shanna D. Kulik, Pieter Wesseling, Tianne Numan, Arjan Hillebrand, Philip C. De Witt Hamer, Jaap C. Reijneveld, Cornelis J. Stam, Martin Klein, Linda Douw   +9 more
openalex   +1 more source

Pattern of failure in IDH mutated, low grade glioma after radiotherapy – Implications for margin reduction [PDF]

, 2020
Jaap Jaspers, Alejandra Méndèz Romero, Ruud Wiggenraad, Inge Compter, Daniëlle B. P. Eekers, Remi A. Nout, Martin J. van den Bent   +6 more
openalex   +1 more source

Inhibition of FOS‐Like Antigen 1 Reduces Chemoresistance to Temozolomide Through Stemness Reprogramming via IL‐6/STAT3Tyr705 Pathway

MedComm, Volume 7, Issue 2, February 2026.
The role of FOSL1 in TMZ response to GBM. FOSL1 enhances TMZ resistance by promoting cell cycle progression, MGMT expression, and IL‐6‐pSTAT3Tyr705‐stemness axis. VEM is a potential candidate drug for alleviating TMZ resistance in GBM, highlighting a new approach for chemo‐resistant GBM treatment.
JeongMin Sim, JeongMan Park, JinHyung Heo, Yu Jin Kim, Dongkil Kim, Yong Hyun Jeon, Jae‐Eon Lee, Seon Hee Choi, Hak Jin Kim, So Jung Hwang, Junhyung Kim, Kyung Gi Cho, Jihwan Yoo, Ju Hyung Moon, Jong‐Seok Moon, Kyoung Su Sung, Jaejoon Lim   +16 more
wiley   +1 more source

Treatment differences in IDH-wildtype glioma - the impact of surgery and adjuvant therapy. [PDF]

J Neurooncol
Keric N, Krenzlin H, Lange F, Dauth A, Freyschlag CF, Schnellg O, Misch M, von der Brelie C, Gempt J, Krigers A, Wagner A, Mielke D, Sommer C, Brockmann MA, Meyer B, Rohde V, Vajkoczy P, Beck J, Thomé C, Ringel F.   +19 more
europepmc   +1 more source

Integrative Single‐Cell Analysis Reveals Targetable Vacuole Membrane Protein 1‐Mediated Mechanism of Tumor Angiogenesis in Glioblastoma

MedComm, Volume 7, Issue 2, February 2026.
VMP1 promotes angiogenesis in glioblastoma (GBM) through VEGFA‐VEGFR2 signaling and activation of endothelial cells. The FDA‐approved anti‐VEGFA antibody, bevacizumab (BEV), can counteract VMP1's tumor‐promoting effect in GBM. Targeting VMP1 or its associated pathways could be a new therapeutic strategy, either alone or in combination with BEV.
Lei Jin, Bo Chen, Junbo Liao, Wenlong Guo, Zhiyuan Zhu, Salida Ali, Gilberto Ka‐Kit Leung, Peng Wang, Karrie M. Kiang   +8 more
wiley   +1 more source

Customized SAM-Med3D with multi-view adapter and T2-FLAIR mismatch features for glioma IDH genotyping and grading. [PDF]

Front Behav Neurosci
Li X, Li H, Hu Y, Zhang J, Wang L, Yang X.   +5 more
europepmc   +1 more source